Table 1.
Patient characteristics patients with collected survey form
| Factors | Categories | Patients with collected survey form, n (%) | Safety analysis set, n (%) | Effectiveness analysis set, n (%) |
|---|---|---|---|---|
| Total | – | 2293 | 2292 | 2235 |
| Age (1) (years)a | < 15 | 1 (0.04) | 1 (0.04) | 1 (0.04) |
| ≥ 15, < 65 | 2188 (95.42) | 2187 (95.42) | 2134 (95.48) | |
| ≥ 65 | 104 (4.54) | 104 (4.54) | 100 (4.47) | |
| Age (2) (years) | < 10 | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| ≥ 10, < 20 | 8 (0.35) | 8 (0.35) | 8 (0.36) | |
| ≥ 20, < 30 | 359 (15.66) | 359 (15.66) | 347 (15.53) | |
| ≥ 30, < 40 | 691 (30.14) | 690 (30.10) | 667 (29.84) | |
| ≥ 40, < 50 | 749 (32.66) | 749 (32.68) | 738 (33.02) | |
| ≥ 50, < 60 | 293 (12.78) | 293 (12.78) | 288 (12.89) | |
| ≥ 60, < 70 | 148 (6.45) | 148 (6.46) | 143 (6.40) | |
| ≥ 70 | 45 (1.96) | 45 (1.96) | 44 (1.97) | |
| n | 2293 | 2292 | 2235 | |
| Mean | 41.1 | 41.1 | 41.2 | |
| SD | 11.8 | 11.8 | 11.7 | |
| Min | 13 | 13 | 13 | |
| Max | 83 | 83 | 83 | |
| Sex | Male | 2182 (95.16) | 2181 (95.16) | 2128 (95.21) |
| Female | 111 (4.84) | 111 (4.84) | 107 (4.79) | |
| CDC classification at pretreatment | A | 1530 (66.72) | 1529 (66.71) | 1498 (67.02) |
| B | 125 (5.45) | 125 (5.45) | 121 (5.41) | |
| C | 538 (23.46) | 538 (23.47) | 529 (23.67) | |
| Unknown | 99 (4.32) | 99 (4.32) | 86 (3.85) | |
| P-0 | 0 (0.00) | 0 (0.00) | 0 (0.00) | |
| P-1 | 0 (0.00) | 0 (0.00) | 0 (0.00) | |
| P-2 | 0 (0.00) | 0 (0.00) | 0 (0.00) | |
| Comorbidities | Absent | 751 (32.75) | 751 (32.77) | 732 (32.75) |
| Present | 1432 (62.45) | 1432 (62.48) | 1401 (62.68) | |
| Unknown | 110 (4.80) | 109 (4.76) | 102 (4.56) | |
| Liver disorder | Absent | 1703 (74.27) | 1703 (74.30) | 1660 (74.27) |
| Present | 449 (19.58) | 449 (19.59) | 443 (19.82) | |
| Unknown | 141 (6.15) | 140 (6.11) | 132 (5.91) | |
| Renal disorder | Absent | 2055 (89.62) | 2055 (89.66) | 2010 (89.93) |
| Present | 160 (6.98) | 160 (6.98) | 155 (6.94) | |
| Unknown | 78 (3.40) | 77 (3.36) | 70 (3.13) | |
| Duration of treatment (days) | ≤ 180 | 141 (6.15) | 140 (6.11) | 112 (5.01) |
| > 180, ≤ 365 | 218 (9.51) | 218 (9.51) | 211 (9.44) | |
| > 365, ≤ 730 | 368 (16.05) | 368 (16.06) | 361 (16.15) | |
| > 730 | 1542 (67.25) | 1542 (67.28) | 1536 (68.72) | |
| Unknown | 24 (1.05) | 24 (1.05) | 15 (0.67) | |
| N | 2269 | 2268 | 2220 | |
| Min | 1 | 2 | 2 | |
| Max | 2323 | 2323 | 2323 | |
| Prescription history of ARV at baseline | ART-naïve | 1040 (45.36) | 1040 (45.38) | 1025 (45.86) |
| ART-experienced | 1220 (53.21) | 1219 (53.18) | 1184 (52.98) | |
| Unknown | 33 (1.44) | 33 (1.44) | 26 (1.16) | |
| ARV backbone at baseline | ABC+/3TC | 902 (39.34) | 902 (39.35) | 878 (39.28) |
| TAF/FTC | 314 (13.69) | 314 (13.70) | 305 (13.65) | |
| TDF+/FTC | 959 (41.82) | 958 (41.80) | 942 (42.15) | |
| Other | 119 (5.19) | 119 (5.19) | 111 (4.97) |
ABC+/3TC abacavir sulfate/lamivudine, ARV antiretroviral, CDC Centers for Disease Control and Prevention, HIV human immunodeficiency virus, Max maximum, Min minimum, SD standard deviation, TAF/FTC tenofovir alafenamide fumarate/emtricitabine, TDF+/FTC tenofovir disoproxil fumarate/emtricitabine
aIn age group (1), patients were classified into three categories: adolescent (< 15 years), adult (≥ 15, < 64), elderly (≥ 65)